On baseline Day 1, subjects will receive Impact Peptide up to a maximum volume of 1,000 mL per feeding for the 90 day treatment period with Relizorb. Blood and urine will be collected to repeat the screening concentration measurements. Standard use of PERT is allowed with daily meals but not permitted with use of Relizorb during enteral feedings. Safety and tolerability will be assessed using a gastrointestinal symptom diary, adverse events and unanticipated adverse device effects.